### BL-H 2 of 4

**Internal request**
Review the data for the inclusion of atezolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease.

**External request**
Submission request from Genentech to consider the recent Food and Drug Administration (FDA) approval to support the inclusion of Tecentriq in the treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Based on the available data and the recent FDA approval, the panel consensus was to include atezolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease. Atezolizumab was added as a category 2A option for the following settings:

- Bladder Cancer
- Upper GU Tract Tumors: Renal Pelvis
- Upper GU Tract Tumors: Urothelial carcinoma of the ureter
- Urothelial Carcinoma of the Prostate
- Primary Carcinoma of the Urethra (urothelial carcinomas only)

See Submission for references.

### BL-H 2 of 4

**Internal request**
Review the data for the inclusion of pembrolizumab as a subsequent systemic therapy for locally advanced or metastatic disease.

**External request**
Submission request from Genentech to consider the recent FDA approval to support the inclusion of Tecentriq in the treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Based on the available data, the panel consensus was to include pembrolizumab as a subsequent systemic therapy for locally advanced or metastatic disease. Pembrolizumab was added as a category 1 option for the following settings:

- Bladder Cancer
- Upper GU Tract Tumors: Renal Pelvis
- Upper GU Tract Tumors: Urothelial carcinoma of the ureter
- Urothelial Carcinoma of the Prostate
- Primary Carcinoma of the Urethra (urothelial carcinomas only)
| Merck & Co, consider adding pembrolizumab as a second-line systemic therapy for advanced or metastatic urothelial cancer (category1). | See Submission for references. |  |  |  |  |